KR102850637B1 - 단백질 타이로신 포스파타아제 억제제 및 그의 사용 방법 - Google Patents

단백질 타이로신 포스파타아제 억제제 및 그의 사용 방법

Info

Publication number
KR102850637B1
KR102850637B1 KR1020237016153A KR20237016153A KR102850637B1 KR 102850637 B1 KR102850637 B1 KR 102850637B1 KR 1020237016153 A KR1020237016153 A KR 1020237016153A KR 20237016153 A KR20237016153 A KR 20237016153A KR 102850637 B1 KR102850637 B1 KR 102850637B1
Authority
KR
South Korea
Prior art keywords
alkyl
cycloalkyl
fluoro
thiadiazolidine
trione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237016153A
Other languages
English (en)
Korean (ko)
Other versions
KR20230074286A (ko
Inventor
엘리엇 파르니
루홀라 카젬 시루디
자오밍 슝
칭웨이 아이. 장
매튜 오코너
제프 할보르센
홍유 자오
크리스티나 바움가르트너
제니퍼 엠. 프로스트
필 킴
제이슨 알. 애보트
앤드류 보그단
크리스토스 이코노모
쉐칭 왕
Original Assignee
칼리코 라이프 사이언시스 엘엘씨
애브비 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 칼리코 라이프 사이언시스 엘엘씨, 애브비 인코포레이티드 filed Critical 칼리코 라이프 사이언시스 엘엘씨
Priority to KR1020257027922A priority Critical patent/KR20250133466A/ko
Publication of KR20230074286A publication Critical patent/KR20230074286A/ko
Application granted granted Critical
Publication of KR102850637B1 publication Critical patent/KR102850637B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/13—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
KR1020237016153A 2018-06-21 2019-06-21 단백질 타이로신 포스파타아제 억제제 및 그의 사용 방법 Active KR102850637B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257027922A KR20250133466A (ko) 2018-06-21 2019-06-21 단백질 타이로신 포스파타아제 억제제 및 그의 사용 방법

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862688226P 2018-06-21 2018-06-21
US62/688,226 2018-06-21
KR1020217001743A KR102533477B1 (ko) 2018-06-21 2019-06-21 단백질 타이로신 포스파타아제 억제제 및 그의 사용 방법
PCT/US2019/038459 WO2019246513A1 (en) 2018-06-21 2019-06-21 Protein tyrosine phosphatase inhibitors and methods of use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217001743A Division KR102533477B1 (ko) 2018-06-21 2019-06-21 단백질 타이로신 포스파타아제 억제제 및 그의 사용 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257027922A Division KR20250133466A (ko) 2018-06-21 2019-06-21 단백질 타이로신 포스파타아제 억제제 및 그의 사용 방법

Publications (2)

Publication Number Publication Date
KR20230074286A KR20230074286A (ko) 2023-05-26
KR102850637B1 true KR102850637B1 (ko) 2025-08-27

Family

ID=67254011

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020237016153A Active KR102850637B1 (ko) 2018-06-21 2019-06-21 단백질 타이로신 포스파타아제 억제제 및 그의 사용 방법
KR1020257027922A Pending KR20250133466A (ko) 2018-06-21 2019-06-21 단백질 타이로신 포스파타아제 억제제 및 그의 사용 방법
KR1020217001743A Active KR102533477B1 (ko) 2018-06-21 2019-06-21 단백질 타이로신 포스파타아제 억제제 및 그의 사용 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020257027922A Pending KR20250133466A (ko) 2018-06-21 2019-06-21 단백질 타이로신 포스파타아제 억제제 및 그의 사용 방법
KR1020217001743A Active KR102533477B1 (ko) 2018-06-21 2019-06-21 단백질 타이로신 포스파타아제 억제제 및 그의 사용 방법

Country Status (23)

Country Link
US (1) US10954202B2 (enExample)
EP (1) EP3810580A1 (enExample)
JP (3) JP7217762B2 (enExample)
KR (3) KR102850637B1 (enExample)
CN (1) CN112955438A (enExample)
AR (1) AR125425A1 (enExample)
AU (3) AU2019290197B2 (enExample)
BR (1) BR112020026086A2 (enExample)
CA (1) CA3104507A1 (enExample)
CL (1) CL2020003316A1 (enExample)
CO (1) CO2021000447A2 (enExample)
CR (1) CR20210017A (enExample)
DO (1) DOP2020000252A (enExample)
EC (1) ECSP21003520A (enExample)
IL (1) IL279587A (enExample)
MA (1) MA52963A (enExample)
MX (2) MX2020014223A (enExample)
PE (2) PE20260750A1 (enExample)
PH (1) PH12020552228A1 (enExample)
SG (1) SG11202012820PA (enExample)
TW (2) TWI888352B (enExample)
UY (2) UY41151A (enExample)
WO (1) WO2019246513A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3765094A4 (en) 2018-03-15 2021-12-22 KSQ Therapeutics, Inc. GENE REGULATORY COMPOSITIONS AND PROCEDURES FOR IMPROVED IMMUNOTHERAPY
TWI888352B (zh) * 2018-06-21 2025-07-01 美商嘉來克生命科學有限責任公司 蛋白質酪胺酸磷酸酯酶抑制劑及其使用方法
KR102983496B1 (ko) * 2019-03-14 2026-06-29 칼리코 라이프 사이언시스 엘엘씨 단백질 티로신 포스파타제 억제제 및 이의 사용 방법
AU2020395612A1 (en) * 2019-12-04 2022-06-09 Monash University Methods of activating cytotoxic leukocytes using PTP1B and PTPN2 inhibitors
AU2020401376A1 (en) 2019-12-12 2022-06-30 Kumquat Biosciences Inc. Compositions and methods for potentiating immune activity
MX2022007441A (es) * 2019-12-18 2022-09-02 Calico Life Sciences Llc Inhibidores de proteína tirosina fosfatasa y sus métodos de uso.
EP4211122A1 (en) * 2020-09-11 2023-07-19 Calico Life Sciences LLC Protein tyrosine phosphatase inhibitors and methods of use thereof
EP4351558A4 (en) * 2021-06-10 2025-05-07 Ness Therapeutics, Inc. Compounds containing 5-(2-fluoro-6-hydroxyphenyl)-1,2,5-thiazolidin-3-one 1,1-dioxide as inhibitors of protein kinase phosphatase enzymes
WO2022271727A1 (en) * 2021-06-21 2022-12-29 Calico Life Sciences Llc Degrader compounds and uses thereof
CN118556055A (zh) * 2021-11-11 2024-08-27 卡里科生命科学有限责任公司 蛋白酪氨酸磷酸酶抑制剂及其使用方法
MX2024005658A (es) * 2021-11-11 2024-08-06 Calico Life Sciences Llc Inhibidores de proteina tirosina fosfatasa y metodos de uso de estos.
IL314650A (en) * 2022-02-02 2024-09-01 Nerio Therapeutics Inc Protein tyrosine phosphatase inhibitors and uses thereof
KR20250011138A (ko) * 2022-05-13 2025-01-21 네스 테라퓨틱스 인코포레이티드 Ptpn2 저해제
CN116675653B (zh) * 2022-07-22 2024-10-01 中国药科大学 氨基烷基取代的1,2,4-噻二唑烷-3,5-二酮化合物及其制备方法和应用
JP2025530135A (ja) * 2022-09-13 2025-09-11 カムクワット バイオサイエンシーズ インコーポレイテッド ベンゾ縮合ｎ－複素環及びその使用
EP4615840A1 (en) * 2022-11-09 2025-09-17 Bristol-Myers Squibb Company Indazol substituted 1,2,5-thiadiazolidin derivatives as inhibitors of protein tyrosine phosphatase (ptpn2) for the treatment of cancer diseases
WO2024243441A1 (en) 2023-05-24 2024-11-28 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
CN117343052B (zh) * 2023-12-04 2024-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用
WO2026112350A1 (en) * 2024-11-22 2026-05-28 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007067612A1 (en) * 2005-12-08 2007-06-14 Novartis Ag 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
KR102533477B1 (ko) * 2018-06-21 2023-05-18 칼리코 라이프 사이언시스 엘엘씨 단백질 타이로신 포스파타아제 억제제 및 그의 사용 방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
EP1439834A1 (en) 2001-10-30 2004-07-28 Applied Research Systems ARS Holding N.V. Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps)
ATE534637T1 (de) 2002-04-03 2011-12-15 Novartis Ag 5-substituierte 1,1-dioxo- 1,2,5 thiazolidin-3- onderivate als ptpase 1b hemmer
GB0225986D0 (en) * 2002-11-07 2002-12-11 Astrazeneca Ab Chemical compounds
AU2003300447B2 (en) 2002-12-30 2009-09-03 Vertex Pharmaceuticals Incorporated Sulfhydantoins as phosphate isosteres for use as phosphatase inhibitors in the treatment of cancer and autoimmune disorders
UA94724C2 (en) 2005-12-08 2011-06-10 Новартис Аг Thiadiazolidinone derivatives as antidiabetic agents
EP1963294B1 (en) 2005-12-08 2012-10-10 Novartis AG 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (ptpase)
RU2008127253A (ru) 2005-12-08 2010-01-20 Новартис АГ (CH) 1,1,3-триоксо-1,2,5-тиадиазолидины и их применение в качестве ингибиторов птфаз
EP1991544B1 (en) 2006-01-30 2018-08-15 vTv Therapeutics LLC Substituted imidazole derivatives and their use as ptpase inhibitors
JP2009532379A (ja) 2006-03-31 2009-09-10 ノバルティス アクチエンゲゼルシャフト ＰＴＰａｓｅのチアジアゾリジノン阻害剤
WO2008142198A2 (en) 2007-05-23 2008-11-27 Valtion Teknillinen Tutkimuskeskus A method for inhibiting or stimulating angiogenesis in an individual
WO2010008852A2 (en) 2008-06-23 2010-01-21 Taiga Biotechnologies, Inc. Methods of trea fing λλd methods of diagnosing an immunoproliferative disorder
US9217012B2 (en) 2009-04-08 2015-12-22 Indiana University Research And Technology Corporation Inhibitors of protein tyrosine phosphatases
WO2011057331A1 (en) 2009-11-11 2011-05-19 Monash University A method for treating obesity
EP2531616A4 (en) 2010-02-03 2013-07-10 Univ Monash DIAGNOSIS AND FORECAST ASSAY FOR BREAST CANCER
CA2977839C (en) 2014-02-28 2022-07-26 The Royal Institution For The Advancement Of Learning / Mcgill University Tc-ptp inhibitors as apc activators for immunotherapy
JP2017524348A (ja) 2014-06-10 2017-08-31 モナッシュ ユニバーシティ 養子細胞移入のためのｐｔｐｎ２阻害を用いた白血球の産生方法
WO2017078499A2 (ko) 2015-11-06 2017-05-11 경북대학교 산학협력단 단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물
KR101826690B1 (ko) 2015-11-06 2018-03-22 경북대학교 산학협력단 단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물
WO2018148378A1 (en) 2017-02-08 2018-08-16 Dana-Farber Cancer Institute, Inc. Modulating biomarkers to increase tumor immunity and improve the efficiacy of cancer immunotherapy
WO2018227248A1 (en) 2017-06-13 2018-12-20 Monash University Methods and compositions for the treatment of obesity
WO2019036815A1 (en) 2017-08-24 2019-02-28 The Royal Institution For The Advancement Of Learning/Mcgill University ENHANCEMENT OF CD8 + T LYMPHOCYTES FOR ADOPTIVE CELL THERAPY BY INHIBITING PTPN1 (PTP1B) AND PTPN2 (TC-PTP))

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007067612A1 (en) * 2005-12-08 2007-06-14 Novartis Ag 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
KR102533477B1 (ko) * 2018-06-21 2023-05-18 칼리코 라이프 사이언시스 엘엘씨 단백질 타이로신 포스파타아제 억제제 및 그의 사용 방법

Also Published As

Publication number Publication date
CO2021000447A2 (es) 2021-07-19
PH12020552228A1 (en) 2021-08-16
MA52963A (fr) 2021-04-28
TW202016082A (zh) 2020-05-01
JP7704787B2 (ja) 2025-07-08
ECSP21003520A (es) 2021-02-26
PE20260750A1 (es) 2026-03-31
CA3104507A1 (en) 2019-12-26
JP2021530443A (ja) 2021-11-11
AU2019290197A1 (en) 2021-01-21
JP7217762B2 (ja) 2023-02-03
SG11202012820PA (en) 2021-01-28
IL279587A (en) 2021-03-01
PE20210372A1 (es) 2021-02-26
TWI888352B (zh) 2025-07-01
UY38272A (es) 2019-12-31
MX2020014223A (es) 2021-06-23
WO2019246513A1 (en) 2019-12-26
CR20210017A (es) 2021-11-03
US10954202B2 (en) 2021-03-23
AU2023263567A1 (en) 2023-11-30
BR112020026086A2 (pt) 2021-03-23
CN112955438A (zh) 2021-06-11
AU2023263567B2 (en) 2026-02-19
KR20230074286A (ko) 2023-05-26
KR102533477B1 (ko) 2023-05-18
US20210009542A1 (en) 2021-01-14
JP2025143330A (ja) 2025-10-01
KR20250133466A (ko) 2025-09-05
AR125425A1 (es) 2023-07-19
JP2023055771A (ja) 2023-04-18
DOP2020000252A (es) 2021-07-15
CL2020003316A1 (es) 2021-06-11
JP7881804B2 (ja) 2026-06-29
UY41151A (es) 2025-09-30
TW202600546A (zh) 2026-01-01
EP3810580A1 (en) 2021-04-28
AU2026203759A1 (en) 2026-06-04
AU2019290197B2 (en) 2023-08-24
MX2024004318A (es) 2024-04-23
KR20210034589A (ko) 2021-03-30

Similar Documents

Publication Publication Date Title
JP7704787B2 (ja) タンパク質チロシンホスファターゼ阻害剤及びそれらの使用方法
JP7751582B2 (ja) タンパク質チロシンホスファターゼ阻害剤及びそれらの使用方法
US10851073B2 (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
US20250122160A1 (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
RU2799446C2 (ru) Ингибиторы протеин-тирозинфосфатазы и способы их применения
RU2833220C2 (ru) Ингибиторы белковых тирозинфосфатаз и способы их применения

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)